Adiponectin: Physiology and What Research Reports

What Is Adiponectin?

Adiponectin is a protein hormone secreted largely by adipose tissue, placing it in the family of signalling molecules known as adipokines. A 2019 review of the mechanisms of adiponectin action reported that the protein circulates as trimers, hexamers and high-molecular-weight multimers, and that it acts through the receptors AdipoR1, AdipoR2 and T-cadherin with downstream effects on AMP-activated protein kinase and ceramide metabolism (PMID 31200595). Because different multimer forms bind receptors differently, researchers frequently distinguish total adiponectin from the high-molecular-weight fraction when they report findings (PMID 31200595).

Is adiponectin a "peptide"?

Readers often meet the phrase "adiponectin peptide". Adiponectin itself is a full-length secreted protein with a collagen-like domain and a globular head rather than a short synthetic peptide, and interest in smaller molecules comes from work on its receptors: a 2017 review reported that AdipoR1 and AdipoR2 carry intrinsic ceramidase activity that is enhanced when adiponectin binds them (PMID 28758149). A 2025 review of adiponectin and adiponectin receptors in atherosclerosis discussed receptor signalling as a target of ongoing pharmacological interest (PMID 39106421).

Where Adiponectin Is Produced

Adipocytes are the dominant source, but the literature describes additional sites and transport routes:

• A 2023 study in Nature Communications reported that endogenous adiponectin produced within the kidney drove gluconeogenesis by enhancing pyruvate and fatty-acid utilisation in mice (PMID 37848446).
• A 2023 Cell Reports study reported that extracellular vesicles act as carriers of adiponectin and that these vesicle-associated pools showed insulin-sensitizing and anti-inflammatory properties (PMID 37605533).
• A 2025 preprint comparing adiponectin-deficient mouse lines reported a fundamental role for intracellular adiponectin, not only the secreted circulating form (PMID 40791378).

What Adiponectin Does in the Body

Insulin sensitivity and fuel handling

The best-described actions relate to glucose and lipid metabolism. The 2019 mechanisms review reported that adiponectin signalling improves insulin sensitivity in part through AMPK activation and through ceramidase-mediated lowering of ceramide levels (PMID 31200595). The 2023 renal study reported that locally produced adiponectin influenced hepatic-style substrate use in kidney tissue, supporting gluconeogenesis from pyruvate and fatty acids (PMID 37848446), which illustrates that adiponectin's metabolic effects are tissue-dependent rather than uniform.

Vascular tissue and the heart

A 2021 review in Circulation Research examined adiponectin alongside leptin in cardiovascular disorders and reported that the two adipokines exert broadly opposing influences on vascular and cardiac tissue (PMID 33411633). The 2025 Endocrine Reviews article summarised experimental evidence that adiponectin receptor signalling modulates processes involved in atherosclerotic plaque biology (PMID 39106421). A 2021 review of adiponectin in heart failure described the clinical picture as more complex, noting the so-called adiponectin paradox in which elevated circulating levels accompany advanced disease (PMID 32915067).

Kidney filtration and fibrosis

A 2008 study in the Journal of Clinical Investigation reported that adiponectin-knockout mice showed increased albuminuria with fusion of podocyte foot processes, and that administering adiponectin reduced albuminuria and improved podocyte structure in those animals (PMID 18431507). A 2020 paper in Aging examined adiponectin in the context of renal fibrosis and reported that adiponectin signalling influenced fibrotic remodelling pathways in the kidney (PMID 32065783).

Skeletal muscle and inflammation

A 2019 review of adiponectin in myopathies reported anti-inflammatory actions in skeletal muscle and discussed adiponectin's relevance to inflammatory and metabolic muscle disease (PMID 30934785). The vesicle study likewise reported anti-inflammatory properties of adiponectin carried on extracellular vesicles (PMID 37605533).

How Adiponectin Is Measured and Studied

Why the Term Appears in Peptide Discussions

Adiponectin is a native human protein, so it turns up in peptide literature in three ways. First, as a biomarker: studies that track metabolic or inflammatory status often report adiponectin concentrations, as the 2024 COVID-19 severity analysis did (PMID 38791005). Second, as a mechanistic reference point, because AMPK and ceramide pathways described in the 2019 mechanisms review overlap with pathways discussed for other metabolic agents (PMID 31200595). Third, as a receptor target, since the 2025 atherosclerosis review framed AdipoR signalling as a subject of continuing preclinical investigation (PMID 39106421). None of the cited work establishes adiponectin or adiponectin-receptor compounds as approved treatments in humans.

Adiponectin Levels and Risks: What Studies Report

Because most human data are observational, the literature reports associations rather than demonstrated safety or harm from raising or lowering adiponectin. The 2021 heart failure review reported that higher circulating adiponectin has been observed in patients with worse clinical status, a finding it described as paradoxical relative to the protein's protective effects in experimental models (PMID 32915067). The 2024 serum study reported that adiponectin levels carried prognostic information for COVID-19 severity, again as a marker rather than an intervention (PMID 38791005). The 2021 Circulation Research review reported that adipokine effects vary by tissue, disease stage and companion signals such as leptin, which complicates simple interpretations of a single blood value (PMID 33411633). Adverse-event data for administered adiponectin in humans are not described in the papers cited here; the reported administration experiments were in mice (PMID 18431507).

Key Takeaways From the Cited Literature

• Adiponectin is an abundant adipose-derived protein acting through AdipoR1, AdipoR2 and T-cadherin, as reported in a 2019 mechanisms review (PMID 31200595).
• Its reported actions span insulin sensitivity, substrate utilisation, vascular biology, kidney podocyte integrity and inflammation (PMID 37848446, PMID 18431507).
• Human evidence is largely associative, and researchers have reported directionally complex findings in heart failure and infection (PMID 32915067, PMID 38791005).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, laboratory testing or treatment. The summaries above describe what the study authors reported in the cited publications and are not guidance for use of any substance.

References

• Mechanisms of Adiponectin Action (International Journal of Molecular Sciences, 2019)
• Adiponectin and its Hydrolase-Activated Receptors (Journal of Nature and Science, 2017)
• Endogenous renal adiponectin drives gluconeogenesis through enhancing pyruvate and fatty acid utilization (Nature Communications, 2023)
• Extracellular vesicles are carriers of adiponectin with insulin-sensitizing and anti-inflammatory properties (Cell Reports, 2023)
• Adiponectin, Leptin and Cardiovascular Disorders (Circulation Research, 2021)
• Adiponectin and Adiponectin Receptors in Atherosclerosis (Endocrine Reviews, 2025)
• Adiponectin in heart failure (Future Cardiology, 2021)
• Adiponectin in renal fibrosis (Aging, 2020)
• Linking adiponectin to proteinuria (The Journal of Clinical Investigation, 2008)
• Adiponectin in Myopathies (International Journal of Molecular Sciences, 2019)
• Serum Adiponectin Predicts COVID-19 Severity (Biomedicines, 2024)
• A comparison of adiponectin-deficient mice reveals the fundamental role of intracellular adiponectin (bioRxiv, 2025)